1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
LSL Pharma Group Inc

LSL Pharma Group Inc

LSL.V
LSL Pharma Group IncCA flagToronto Stock Exchange Ventures
0.30
CAD
+0.01
- -
37.39MMarket Cap

Total Valuation

LSL Pharma Group Inc carries a market capitalization of 37.39M, placing it among publicly traded companies globally. Its enterprise value stands at 89.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap37.39M
Enterprise Value89.55M

Share Statistics

LSL Pharma Group Inc currently has 126.73M shares outstanding.

Shares Outstanding126.73M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

LSL Pharma Group Inc trades at a trailing price-to-earnings ratio of 12.09. The price-to-sales ratio is 0.93, and the price-to-book ratio stands at 1.82.

PE Ratio12.09
PS Ratio0.93
PB Ratio1.82
P/TBV Ratio399.20
P/FCF Ratio-109.15
P/OCF Ratio-6.65

Enterprise Valuation

On an enterprise value basis, LSL Pharma Group Inc trades at an EV/EBITDA multiple of 394.28 and an EV/FCF ratio of 28.35. The EV/Sales ratio of 2.14 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 55.77 provides insight into valuation relative to core operating earnings.

EV / Sales2.14
EV / EBITDA394.28
EV / EBIT55.77
EV / FCF28.35

Financial Position

LSL Pharma Group Inc maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 230.22, indicating elevated leverage, while an interest coverage ratio of -0.78 demonstrates limited ability to service its debt obligations.

Current Ratio1.16
Quick Ratio0.37
Debt / Equity230.22
Debt / EBITDA-18.46
Interest Coverage-0.78

Financial Efficiency

Return on Equity (ROE)-31.63
Return on Assets (ROA)-9.85
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.61

Stock Price Statistics

LSL Pharma Group Inc's stock has declined approximately -20.27027% over the past 52 weeks. The 50-day moving average sits at 0.34, while the 200-day moving average is 0.38.

Beta (5Y)N/A
52-Week Price Change-20.27027%
50-Day Moving Average0.34
200-Day Moving Average0.38
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, LSL Pharma Group Inc generated 41.83M in revenue and converted that into -7.33M in net income, yielding earnings per share of -0.06. EBITDA reached -2.74M, while operating income came in at -5.98M.

Revenue41.83M
Gross Profit3.45M
Operating Income-5.98M
Pretax Income-7.40M
Net Income-7.33M
EBITDA-2.74M
EBIT-5.98M
Earnings Per Share (EPS)-0.06

Balance Sheet

LSL Pharma Group Inc holds 967,000.00 in cash and equivalents against 50.59M in total debt, resulting in a net debt position of 36.20M. Total book value stands at 21.98M, with working capital of 3.68M providing operational flexibility.

Cash & Cash Equivalents967,000.00
Total Debt50.59M
Net Debt36.20M
Equity (Book Value)21.98M
Book Value Per Share0.17
Working Capital3.68M

Cash Flow

LSL Pharma Group Inc produced -5.86M in operating cash flow over the past twelve months. After subtracting -5.50M in capital expenditures, free cash flow totaled -11.36M - equivalent to -0.09 per share.

Operating Cash Flow-5.86M
Capital Expenditures-5.50M
Free Cash Flow-11.36M
FCF Per Share-0.09

Margins

LSL Pharma Group Inc operates with a gross margin of 8.26, reflecting its pricing power and cost economics. The operating margin of -14.31 and net profit margin of -17.54 provide insight into operational efficiency.

Gross Margin8.26
Operating Margin-14.31
Pretax Margin-17.69
Profit Margin-17.54
EBITDA Margin-6.55

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-24.69
FCF Yield-0.92

Scores

LSL Pharma Group Inc posts an Altman Z-Score of 0.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.28